Boston, MA 05/28/2013 (wallstreetpr) – In Friday’s trading session, Oragenics Inc (NYSEMKT:OGEN) rose by 21.38%. It opened at $2.79 per share, touched an intraday high of $3.35 and dropped down to close at $2.74 per share. More than 0.227 million shares were traded in Friday’s trading session. This number stood above the average volume of 0.128 million that was measured over a 30-day period.
Oragenics Inc (NYSEMKT:OGEN) is highly focused on becoming the world-leader in novel antibiotics. These are used to fight against infectious disease and its probiotics are used for oral health for humans as well as pets. The company has established a very exclusive, global channel collaboration that is used for lantibiotics. This is a novel class of various broad spectrum antibiotics. It has a collaboration with a synthetic biology company, Intrexon Corporation Inc. This collaboration allows Oragenics Inc (NYSEMKT:OGEN) access to Intrexon Corporation Inc’s proprietary technologies. The objective of the alliance is to accelerate the development of the much needed newer antibiotics. These are meant to work against various resistant bacteria strains.
Oragenics Inc (NYSEMKT:OGEN) is also involved in developing, marketing and selling proprietary probiotics. These probiotics are designed specifically to improve oral health for humans as well as for pets. They are sold under the Evora and ProBiora brand names in more than 13 countries across the globe. The company’s SMaRT Replacement Therapy is specially designed as a treatment that has to be applied directly to the teeth. It has the ability to protect against tooth decay or dental caries
